COVID-19: A Global Pandemic of 21st Century

In last of 2019, the Centers for Disease Control and Prevention started monitoring the outbreak of a new corona virus, SARS-CoV-2, which causes the respiratory illness now known as COVID-19. Authorities first identified the virus in Wuhan, China. More than 82542 case of Corona virus in China at 31 March 2020. Health authorities have identified many other people with COVID-19 around the world. On 31 March 2020, the virus spread more than 750890 People in the World. The World Health Organization (WHO) has declared a public health emergency relating to COVID-19. Since then, this strain has been diagnosed in several residents of world. The CDC have advised that it is likely to spread to more people. COVID-19 has affected at least 213 countries or territories or areas. The first people with COVID-19 had links to an animal and seafood market. This fact suggested that animals initially transmitted the virus to humans. However, people with a more recent diagnosis had no connections with or exposure to the market, confirming that humans can pass the virus to each other. Corona viruses will infect most people at some time during their lifetime. Corona viruses can mutate effectively, which makes them so contagious. Information on the virus is scarce at present. In the past, respiratory conditions that develop from corona viruses, such as SARS and MERS, have spread through close contacts. On 17 February 2020, the Director-General of the WHO presented at a media briefing the following updates on how often the symptoms of COVID-19.However, while some viruses are highly contagious, it is less clear how rapidly corona viruses will spread. Symptoms vary from person-to-person with COVID-19. It may produce few or no symptoms. However, it can also lead to severe illness and may be fatal. On 11 March 2020, WHO declared Novel Corona virus Disease (COVID-19) outbreak as a Pandemic. Keywords: WHO, ICMR, SARS-CoV-2, Bats, Wuhan City, Pneumonia, Respiratory Infection, Pandemi

PREPARE AND EVALUATE MUCOADHESIVE FORMULATIONS OF LAMIVUDINE WITH BETTER CONTROLLED/ SUSTAINED DRUG RELEASE PROFILE

The aim of present study was to formulate & evaluate the mucoadhesive sustained release formulations of lamivudine and to fulfill this aim, two mucoadhesive formulations Gels and Tablets were prepared by using three different polymers: HPMC K15, poloxamer 407 & carbopol 934. Three mucoadhesive gel and nine tablet formulations were prepared and evaluated for various parameters. All three gels were able to give sustained release up to 12 hours. Tablet formulations, F1 to F5 failed to fulfill the aim. Only F6, F7, F8 & F9 formulations were selected, as all gave sustained release up to 12 hours, except F6, which gave sustained release profile only till 7 hours. From the drug release plots, it was concluded that the type of polymer and concentration of polymer have distinct effect on in vitro drug release profile and all the formulations follow first order mechanism with anomalous diffusion or non-fickian diffusion, except carbopol gel and poloxamer tablets. Carbopol gel follows zero order release rate with super case II transport and poloxamer tablets (F6) follow higuchi with non-fickian diffusion. It is concluded that mucoadhesive formulations of lamivudine can be prepared for sustaining its release. And the successful outcome of the present study also encourage for further studies to assess the ability of the mucoadhesive formulations of lamivudine in providing an effective sustained and safe therapy for AIDS

HCFC1 is a common component of active human CpG-island promoters and coincides with ZNF143, THAP11, YY1, and GABP transcription factor occupancy.

In human transcriptional regulation, DNA-sequence-specific factors can associate with intermediaries that orchestrate interactions with a diverse set of chromatin-modifying enzymes. One such intermediary is HCFC1 (also known as HCF-1). HCFC1, first identified in herpes simplex virus transcription, has a poorly defined role in cellular transcriptional regulation. We show here that, in HeLa cells, HCFC1 is observed bound to 5400 generally active CpG-island promoters. Examination of the DNA sequences underlying the HCFC1-binding sites revealed three sequence motifs associated with the binding of (1) ZNF143 and THAP11 (also known as Ronin), (2) GABP, and (3) YY1 sequence-specific transcription factors. Subsequent analysis revealed colocalization of HCFC1 with these four transcription factors at ∼90% of the 5400 HCFC1-bound promoters. These studies suggest that a relatively small number of transcription factors play a major role in HeLa-cell transcriptional regulation in association with HCFC1

Pharmacological Modeling and Study for Antidiabetic Activity of Praecitrullus fistulosus Leaves Extracts

Phytochemical and pharmacological investigations of leaves of Praecitrullus fistulosus for the antidiabetic activity have been done in our research work encompassed in depth and systematic screening of plant leaves and further extraction, characterization and bioevaluation. The research was envisaged for antidiabetic activity of different extracts procured by successive extraction methods and to find out or isolate the most possible active compounds from the active extracts showing the best activity. The antidiabetic activity of all extracts has been evaluated by STZ induced diabetes. The isolated compounds have been evaluated by in-vitro and in-vivo models. The alcohol soluble extractives values were found to be higher than water soluble extractive value. Alcohol being a moderately non polar solvent, able to extract polar and non-polar components yields higher extractive value. The ethanol extract shows significant enhancement in glucose tolerance in glucose fed hyperglycemic normal rats and produced a marked decrease in blood glucose levels at 200 mg/kg and 400 mg/kg body weight in streptozotocin-diabetic rats after 21 days treatment. Keywords: Praecitrullus fistulosus, Streptozotocin and Glibenclamide, diabetes, Pharmacological Evaluatio